Idogen’s IDO 8 granted orphan drug designation in the USA
Idogen AB (”Idogen”) today annonces that the US Medicines Agency, the FDA, has granted the company´s cell therapy IDO 8 orphan drug designation in the United States as a treatment to reduce factor VIII neutralizing antibodies. These antibodies or inhibitors occur in about 30 % of patients with haemophilia A who are treated with factor VIII concentrates. Factor VIII neutralizing antibodies can also develop in people with normal levels of factor VIII, and interfere with the activity the clotting factor, a condition also called acquired haemophilia A. Orphan drug designation gives several